InsiderSignal.AI

InsiderSignal.ai

AGIO - Agios Pharmaceuticals, Inc.

Insider Sale by Gheuens Sarah (Chief Medical Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Gheuens Sarah, serving as Chief Medical Officer at Agios Pharmaceuticals, Inc. (AGIO), sold 2,940 shares at $34.71 per share, for a total transaction value of $102,047.00. Following this transaction, Gheuens Sarah now holds 80,277 shares of AGIO.

This sale represents a 4.00% decrease in Gheuens Sarah's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, April 2, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, 4 days after the trade was made.

Agios Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Gheuens Sarah

Gheuens Sarah

Chief Medical Officer

Sarah Gheuens, M.D., Ph.D. is the Chief Medical Officer (CMO) and Head of Research & Development at Agios Pharmaceuticals, Inc. (AGIO).[[1]](https://www.agios.com/about-us/leadership/sarah-gheuens-m-d-ph-d/)[[2]](https://fintool.com/app/research/companies/AGIO/people/sarah-gheuens)[[6]](https://www.agios.com/about-us/leadership/) She joined Agios in December 2019 as head of clinical development for genetically defined disease programs and interim head of regulatory affairs, became CMO in September 2021, and assumed R&D leadership in August 2022.[[1]](https://www.agios.com/about-us/leadership/sarah-gheuens-m-d-ph-d/)[[2]](https://fintool.com/app/research/companies/AGIO/people/sarah-gheuens) Under her tenure, she led the pivotal Phase 3 programs for pyruvate kinase deficiency (resulting in regulatory submissions to FDA and EMA), thalassemia, and sickle cell disease, with key 2024 milestones including positive Phase 3 readouts in thalassemia (ENERGIZE/ENERGIZE-T) and sNDA acceptance by FDA (PDUFA September 7, 2025).[[1]](https://www.agios.com/about-us/leadership/sarah-gheuens-m-d-ph-d/)[[2]](https://fintool.com/app/research/companies/AGIO/people/sarah-gheuens) Recently, as a corporate insider, she sold 2,932 shares of AGIO stock on December 30, 2025.[[7]](https://www.investing.com/news/insider-trading-news/agios-pharma-chief-medical-officer-gheuens-sells-79k-in-stock-93CH-4428446) Prior to Agios, Dr. Gheuens held roles of increasing responsibility at Biogen (2012–2019) in safety, medical affairs, and clinical development, contributing to the approval of SPINRAZA® for spinal muscular atrophy, and worked as a physician-scientist at Beth Israel Deaconess Medical Center (2008–2012) treating HIV patients with neurological complications and researching progressive multifocal leukoencephalopathy.[[1]](https://www.agios.com/about-us/leadership/sarah-gheuens-m-d-ph-d/)[[2]](https://fintool.com/app/research/companies/AGIO/people/sarah-gheuens)[[3]](https://investors.viridiantherapeutics.com/news/news-details/2023/Viridian-Appoints-Sarah-Gheuens-M.D.-Ph.D.-to-its-Board-of-Directors-09-25-2023/default.aspx) She serves on the Board of Directors and Science & Technology Committee at Viridian Therapeutics, Inc.[[2]](https://fintool.com/app/research/companies/AGIO/people/sarah-gheuens)[[3]](https://investors.viridiantherapeutics.com/news/news-details/2023/Viridian-Appoints-Sarah-Gheuens-M.D.-Ph.D.-to-its-Board-of-Directors-09-25-2023/default.aspx) Dr. Gheuens earned her M.D. from the Free University of Brussels (VUB), completed neurology residency and HIV/neurology fellowship there and at BIDMC, holds a Ph.D. in Medical Sciences from the University of Antwerp, and a Master’s in Medical Sciences from Harvard Medical School.[[1]](https://www.agios.com/about-us/leadership/sarah-gheuens-m-d-ph-d/)[[2]](https://fintool.com/app/research/companies/AGIO/people/sarah-gheuens)

View full insider profile →

Trade Price

$34.71

Quantity

2,940

Total Value

$102,047.00

Shares Owned

80,277

Trade Date

Thursday, April 2, 2026

7 days ago

SEC Filing Date

Monday, April 6, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Agios Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning AGIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5420153

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime